Intarcia vs. Novo: Which has the most appealing diabetes PhIII program?

Now that Intarcia has come out ahead of Merck's ($MRK) Januvia in the latest study of its implanted extended-release option ITCA-650, some analysts are wondering how the next wrinkle in the big diabetes drug competition will play out. Over at EPVantage, that discussion has centered around Novo Nordisk's ($NVO) newly announced Phase IIIa program for oral semaglutide. Both the Novo pill and the Intarcia implant could carve out market share from the GLP-1 class, says EPVantage. So which would patients prefer? Intarcia is likely to be the first to test the market, with plans to file in the first half of 2016. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.